Certara, Inc. (NASDAQ:CERT) Receives $15.29 Average Price Target from Analysts

Certara, Inc. (NASDAQ:CERT) has been assigned an average rating of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $15.29.

A number of research analysts have weighed in on CERT shares. KeyCorp decreased their target price on shares of Certara from $18.00 to $15.00 and set an “overweight” rating on the stock in a research note on Monday, July 14th. Barclays raised Certara from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $11.00 to $14.00 in a report on Thursday, May 8th. JMP Securities reissued a “market perform” rating on shares of Certara in a research note on Tuesday, May 6th. Morgan Stanley began coverage on Certara in a report on Thursday, July 3rd. They issued an “equal weight” rating and a $16.00 target price for the company. Finally, Robert W. Baird raised their target price on Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, April 11th.

Certara Stock Performance

Shares of NASDAQ:CERT opened at $10.64 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.78 and a quick ratio of 2.78. Certara has a 1 year low of $8.64 and a 1 year high of $16.18. The firm has a market capitalization of $1.73 billion, a PE ratio of -532.00 and a beta of 1.43. The business’s 50 day moving average price is $11.13 and its 200-day moving average price is $11.85.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.04. Certara had a positive return on equity of 5.05% and a negative net margin of 0.67%. The company had revenue of $106.00 million for the quarter, compared to analyst estimates of $104.44 million. During the same quarter last year, the firm posted $0.10 EPS. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. As a group, equities research analysts expect that Certara will post 0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Certara

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CERT. ArrowMark Colorado Holdings LLC increased its position in shares of Certara by 164.2% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company’s stock worth $66,171,000 after purchasing an additional 3,861,674 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in Certara by 864.0% during the fourth quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company’s stock worth $40,253,000 after buying an additional 3,387,590 shares during the period. Mackenzie Financial Corp acquired a new stake in shares of Certara during the fourth quarter valued at about $17,852,000. Brown Brothers Harriman & Co. increased its position in shares of Certara by 63.8% during the fourth quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company’s stock valued at $40,668,000 after acquiring an additional 1,487,998 shares during the last quarter. Finally, ExodusPoint Capital Management LP purchased a new stake in shares of Certara in the 4th quarter valued at approximately $11,542,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.